Brief: Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
04/02/2025 13:41
Feb 4 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS COMPLETES ENROLLMENT IN EXPLORE-CKD
PHASE
2 TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION IN
SUBJECTS WITH STAGE 2 TO 3B CKD AND ALBUMINURIA
* MINERALYS THERAPEUTICS INC - TO SHARE TOPLINE DATA FROM
EXPLORE-CKD TRIAL IN Q2 2025
Source text: ID:nGNX4dfjTL
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway